Get the Daily Brief
Latest Biotech News
Adaptive projects MRD growth as ClonoSeq adoption expands
Adaptive Biotechnologies set 2026 guidance expecting 20–30% growth in its minimal residual disease (MRD) business, driven by broader ClonoSeq adoption across hematologic malignancies, higher test...
ARPA‑H trims commercialization ranks: layoffs hit translation staff
ARPA‑H cut approximately 20 employees and contractors from roles tied to operations and commercialization, according to multiple sources and an HHS confirmation. The agency said scientific staff...
Generate:Biomedicines files IPO — AI‑designed antibody programs in view
Flagship Pioneering‑backed Generate:Biomedicines filed for an IPO, spotlighting its AI‑engineered candidates including an anti‑TSLP program entering Phase 3 and other antibody and CAR‑T assets....
Priovant’s brepocitinib posts strong Phase 2 signal in cutaneous sarcoidosis
Priovant Therapeutics, a Roivant spinout, reported that brepocitinib — a TYK2/JAK1 inhibitor obtained from Pfizer — significantly outperformed placebo in a small Phase 2 study of cutaneous...
Bayer’s asundexian cuts recurrent stroke risk: Phase 3 shows 26% reduction
Bayer reported Phase 3 results showing its Factor XIa inhibitor asundexian reduced the risk of secondary ischemic stroke by 26% without increasing major bleeding. The data, presented by Bayer and...
UniQure halts higher-dose Fabry gene arm after liver toxicity; Aro posts Pompe data
UniQure paused mid- and high-dose cohorts in its Fabry gene therapy trial after two patients at 4x10^13 gc/kg experienced grade 3 liver enzyme elevations, the company said in a safety update. The...
Adaptive Biotechnologies pins 2026 growth on MRD testing: ClonoSeq adoption driving revenue
Adaptive Biotechnologies projected at least 20% year-over-year MRD revenue growth for 2026, driven by increased adoption of its ClonoSeq minimal residual disease assay across oncology settings and...
Illumina steadies: clinical consumables climb while overall revenue flat in 2025
Illumina reported flat full‑year 2025 revenue but a meaningful uptick in clinical sequencing consumables, which management said rose on increased uptake of sequencing‑based diagnostics including...
Eikon’s $381M IPO revives biotech listings — proceeds to fund oncology trials
Eikon Therapeutics priced an upsized IPO at $381 million, the largest biotech float since 2024, and said proceeds will prioritize development of EIK‑1001 and other oncology candidates. The...
Generate:Biomedicines files for IPO — AI‑designed antibodies move toward clinic
Generate:Biomedicines, the Flagship Pioneering‑backed AI drug company, filed to go public while highlighting GB‑0895 and other antibody programs as IPO priorities. The filing arrives as the sector...
Veradermics prices $256M IPO — oral minoxidil trials to fund pivotal work
Veradermics priced an upsized $256.3 million IPO to fund pivotal trials of its oral minoxidil formulation (VDPHL‑01) targeting pattern hair loss. Management said the cash will support three...
FDA safety notice: DPYD deficiency labeling update applies to both Xeloda and 5‑FU
The FDA issued a safety communication clarifying that the DPYD (dihydropyrimidine dehydrogenase) deficiency labeling update applies to both capecitabine (Xeloda) and intravenous 5‑fluorouracil...
BARDA launches $100M antiviral prize to seed broad‑spectrum small‑molecule programs
BARDA opened the first phase of a $100 million prize competition aimed at advancing broad‑spectrum small‑molecule antivirals against Togaviridae and Flaviviridae families. The agency will award...
BIO hails pediatric PRV reauthorization and PBM reforms — industry incentive restored
The Biotechnology Innovation Organization (BIO) praised Congress’s reauthorization of the Pediatric Priority Review Voucher (PPRV) through 2029 and inclusion of PBM reform measures in the recent...
IPO revival: Eikon leads biotech float wave
Eikon Therapeutics priced an upsized initial public offering that raised roughly $381 million to fund clinical development of its oncology-focused programs. The company, built around...
Wegovy knockoffs... Telehealth seller draws regulator heat
Hims & Hers began offering a compounded pill version of Novo Nordisk’s Wegovy shortly after the FDA approved the branded oral formulation, prompting immediate industry and regulatory scrutiny. The...
GLP-1 market split: Lilly surges as Novo warns of slowdown
Eli Lilly reported financial results and guidance that outperformed expectations, driven by robust sales of tirzepatide products (Mounjaro/Zepbound), and sent its stock sharply higher. Lilly...
Stroke drug breakthrough: Bayer’s asundexian posts Phase 3 win
Bayer disclosed Phase 3 results showing its factor XIa inhibitor asundexian reduced recurrent ischemic stroke by 26% versus comparator in a secondary‑prevention population, with no major safety...
Brepocitinib shows strong mid‑stage efficacy in rare skin diseases
Roivant spinout Priovant reported Phase 2 data showing brepocitinib—a TYK2/JAK1 inhibitor inherited from Pfizer—significantly outperformed placebo in cutaneous sarcoidosis, registering...
BARDA offers $100m prize to accelerate broad‑spectrum antivirals
The U.S. Biomedical Advanced Research and Development Authority (BARDA) launched the first stage of a $100 million prize competition aimed at stimulating development of broad‑spectrum,...